Volume 5.18 | May 23

Prostate Cell News 5.18 May 23, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Trichomonas vaginalis Homolog of Macrophage Migration Inhibitory Factor Induces Prostate Cell Growth, Invasiveness, and Inflammatory Responses
T. vaginalis macrophage migration inhibitory factor increases the in vitro growth and invasion through Matrigel of benign and prostate cancer cells. [Proc Natl Acad Sci USA] Abstract
ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays - FREE Sample Request
PUBLICATIONS (Ranked by impact factor of the journal)

Targeting Poly(ADP-Ribose) Polymerase and the c-Myb-Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer
Scientists found that MYB is transcriptionally activated by androgen deprivation therapy or genetic silencing of the androgen receptor. MYB silencing inhibited prostate cancer growth in culture and xenografts in mice. [Sci Signal] Abstract

Evaluating the Anticancer Properties of Liposomal Copper in a Nude Xenograft Mouse Model of Human Prostate Cancer: Formulation, In Vitro, In Vivo, Histology and Tissue Distribution Studies
A stealth liposomal Cu formulation (LpCu) was studied in vitro and in vivo. LpCu was evaluated in prostate cancer origin PC-3 cells by a metabolic cytotoxicity assay, by monitoring ROS, and by flow cytometry. [Pharm Res] Abstract

Antitumor Effects of Oncolytic Adenovirus Armed with PSA-IZ-CD40L Fusion Gene against Prostate Cancer
Scientists developed a prostate cancer-specific oncolytic adenovirus armed with fusion gene of prostate-specific antigen and CD40 ligand, and evaluated its therapeutic effect in vitro and in vivo. [Gene Ther] Abstract

Hsa-miRNA-765 as a Key Mediator for Inhibiting Growth, Migration and Invasion in Fulvestrant-Treated Prostate Cancer
Scientists report hsa-miR-765 as the first fulvestrant-driven, estrogen receptor β-regulated miRNA exhibiting significant tumor suppressor activities like fulvestrant, against prostate cancer cell growth via blockage of cell-cycle progression at the G2/M transition, and cell migration and invasion possibly via reduction of filopodia/intense stress-fiber formation. [PLoS One] Full Article | Press Release

Rac1-Dependent Lamellipodial Motility in Prostate Cancer PC-3 Cells Revealed by Optogenetic Control of Rac1 Activity
Researchers revealed the role of phosphatidylinositol 3-kinase in Rac1-dependent lamellipodial motility in PC-3 prostate cancer cells. [PLoS One] Full Article

Metformin Sensitizes Prostate Cancer Cells to Radiation Through EGFR/p-DNA-PKCS In Vitro and In Vivo
Researchers investigated the effects of metformin, a widely used antidiabetic drug, on tumor cell radiosensitivity in prostate cancer. Through clonogenic survival assays, they found that metformin treatment enhanced radiosensitivity of prostate cancer cells with a dose enhancement factor. [Radiat Res] Abstract

Chrebp Regulates the Transcriptional Activity of Androgen Receptor in Prostate Cancer
By way of immunoprecipitation followed by mass spectrometry system, researchers found that carbohydrate-responsive element-binding protein (Chrebp), a glucose sensor in normal and cancer cells, interacted with androgen receptor in LNCaP cells. [Tumor Biol] Abstract

Restoration of Fibroblast Growth Factor Receptor 2IIIb Enhances the Chemosensitivity of Human Prostate Cancer Cells
Researchers determined whether fibroblast growth factor receptor 2 (FGFR2)IIIb plays a role in the chemosensitivity of castration-resistant prostate cancer cells. The effects of chemotherapeutic agents on cell viability and apoptosis were examined by MTT assay and western blot analysis, respectively. [Oncol Rep] Abstract


Randomized Phase II Study of Nintedanib in Metastatic Castration-Resistant Prostate Cancer Postdocetaxel
This open-label, Phase II trial assessed the efficacy and safety of two doses of nintedanib, a triple angiokinase inhibitor targeting vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor signaling, in patients with metastatic castration-resistant prostate cancer following progression on docetaxel-based regimens. [Anticancer Drugs] Abstract

Diagnostic Ability of %p2PSA and Prostate Health Index for Aggressive Prostate Cancer: A Meta-Analysis
Scientists conducted a meta-analysis to evaluate the diagnostic performance of [-2]proPSA/free PSA (%p2PSA) and prostate health index tests for prostate cancer and to evaluate their ability in discriminating between aggressive and non-aggressive prostate cancer. [Sci Rep] Full Article

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now
Evolution of Androgen Receptor Targeted Therapy for Advanced Prostate Cancer
The authors revisit the discovery and evolution of androgen receptor targeting therapeutics for the treatment of advanced-stage prostate cancer over the years and discuss the upcoming future and challenges in the treatment of this common cancer. [Nat Rev Clin Oncol] Abstract

Targeting the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer: Progresses and Prospects
The authors summarize molecular mechanisms of castration resistance and provide an update in the development of novel agents and strategies to more effectively target the androgen receptor signaling pathway. [Oncogene] Abstract

Vaccine Immunotherapy for Prostate Cancer: From Mice to Men
A series of preclinical studies have demonstrated the superiority of the adenovirus/prostate-specific antigen (Ad/PSA) vaccine to other PSA vaccines for the induction of anti-PSA immune responses, the ability of Ad/PSA vaccination combined with cytokine gene therapy and the TLR9 agonist CpG to enhance the anti-prostate tumor immunotherapy, and the reduction of negative regulatory elements when the vaccine was combined with 5-fluoruracil administration. [Immunol Res] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Treatment with PROVENGE® (Sipuleucel-T) Induces Antigen Spread Associated with Overall Survival Benefits in Advanced Prostate Cancer
Dendreon Corporation announced the presentation of data from the ProACT and IMPACT studies suggesting that PROVENGE® (sipuleucel-T) elicits an immune response associated with an overall survival benefit. [Press release from Dendreon Corporation discussing research presented at the 2014 American Urological Association (AUA) Annual Meeting, Orlando] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
Calibr Receives Grant from the Wellcome Trust to Develop a Novel Immunotherapy to Treat Prostate Cancer
The California Institute for Biomedical Research (Calibr) has received a Translation Award from the Wellcome Trust to develop a novel semi-synthetic antibody-based immunotherapy to treat hormone-refractory prostate cancer. [PR Newswire Association LLC] Press Release

SOTIO Initiates VIABLE, a Global Phase III Clinical Trial for Prostate Cancer Immunotherapy Treatment with DCVAC/PCa
SOTIO announced that the first patient has enrolled in its VIABLE study, the global Phase III clinical trial for DCVAC/PCa, an active cellular immunotherapy treatment for prostate cancer patients. [SOTIO, LLC]
Press Release

ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune
ADC Therapeutics announced that it has selected its first IND candidate under its joint development agreement with MedImmune, the global biologics research and development arm of AstraZeneca. [ADC Therapeutics]
Press Release

Bold Initiative to Transform Cancer Care Established with a $100 Million Gift
Memorial Sloan Kettering Cancer Center announced the creation of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology (CMO). Named in honor of Marie-Josée and Henry R. Kravis and the $100 million gift from their foundation, the CMO will enable researchers to speed the translation of new discoveries into routine clinical practice and reshape the design of clinical trials. [Memorial Sloan Kettering Cancer Center]
Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Targeting VEGF-Mediated Tumor Angiogenesis in Cancer Therapy
June 19-20, 2014
New York, United States

Visit our events page to see a complete list of events in the prostate cell community.
NEW Research Fellow – Molecular Mechanisms of Prostate Cancer (Northwestern University- Feinberg School of Medicine)

NEW Research Coordinator / Research Assistant – Oncology (NYU Langone Medical Center Department of Pathology)

NEW PhD Research Project – Role of Leukemia Inhibitory Factor in Prostate Cancer Bone Metastases (Nuffield Department of Surgical Sciences, University of Oxford)

NEW Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Research Associate – Prostate Cancer Research (Medical University of South Carolina)

Postdoctoral Fellow – Translational Prostate Cancer (Cleveland Clinic)

Postdoctoral Researcher – Therapeutic Targets for Cancer Treatment (Sanford Burnham Medical Research Institute)

PhD Position – 3D Cell Culture & Microfluidics: New Insights in Prostate Cancer (CEA French Atomic and Alternative Energies Commission)

Studentship – Targeting WW Domain Function in Ubiquitin Ligases Overexpressed in Prostate Cancer (University of East Anglia)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Research Technologist – hPSC (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Prostate Cell News: Archives | Events | Contact Us